769.525 USD
+6.88 (+0.9%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 525 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year REGN was profitable.
- In the past year REGN had a positive cash flow from operations.
- REGN had positive earnings in each of the past 5 years.
- Each year in the past 5 years REGN had a positive operating cash flow.
1.2 Ratios
- REGN has a Return On Assets of 11.40%. This is amongst the best in the industry. REGN outperforms 94.29% of its industry peers.
- REGN has a Return On Equity of 14.79%. This is amongst the best in the industry. REGN outperforms 94.67% of its industry peers.
- REGN's Return On Invested Capital of 8.69% is amongst the best of the industry. REGN outperforms 94.48% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for REGN is significantly below the industry average of 18.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
- The Profit Margin of REGN (32.13%) is better than 96.57% of its industry peers.
- In the last couple of years the Profit Margin of REGN has grown nicely.
- REGN has a Operating Margin of 27.61%. This is amongst the best in the industry. REGN outperforms 96.57% of its industry peers.
- REGN's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 86.28%, REGN belongs to the top of the industry, outperforming 88.95% of the companies in the same industry.
- REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
- REGN has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, REGN has less shares outstanding
- The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
- REGN has an Altman-Z score of 7.53. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.53, REGN is in the better half of the industry, outperforming 77.52% of the companies in the same industry.
- The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of REGN (0.70) is better than 94.67% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 61.90% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.53 |
ROIC/WACC1.01
WACC8.64%
2.3 Liquidity
- A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
- REGN has a Current ratio (4.06) which is comparable to the rest of the industry.
- REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
- REGN's Quick ratio of 3.51 is in line compared to the rest of the industry. REGN outperforms 44.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- The earnings per share for REGN have decreased by -0.92% in the last year.
- REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
- The Revenue has been growing slightly by 2.89% in the past year.
- Measured over the past years, REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
- REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.62% yearly.
- REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.08% yearly.
EPS Next Y-3.22%
EPS Next 2Y0.63%
EPS Next 3Y6.96%
EPS Next 5Y7.62%
Revenue Next Year0.43%
Revenue Next 2Y3.61%
Revenue Next 3Y5.78%
Revenue Next 5Y6.08%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- REGN is valuated rather expensively with a Price/Earnings ratio of 17.10.
- 95.43% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
- REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.25.
- With a Price/Forward Earnings ratio of 16.65, REGN is valued correctly.
- 95.05% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 25.98. REGN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.1 | ||
| Fwd PE | 16.65 |
4.2 Price Multiples
- REGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. REGN is cheaper than 94.86% of the companies in the same industry.
- 95.43% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.84 | ||
| EV/EBITDA | 15.36 |
4.3 Compensation for Growth
- The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.3
EPS Next 2Y0.63%
EPS Next 3Y6.96%
5. Dividend
5.1 Amount
- REGN has a yearly dividend return of 0.47%, which is pretty low.
- REGN's Dividend Yield is rather good when compared to the industry average which is at 1.08. REGN pays more dividend than 98.29% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
5.2 History
- REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.63%
EPS Next 3Y6.96%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.